Bristol-Myers Squibb Co Stock Price, News & Analysis
Company Description
Bristol-Myers Squibb Company (NYSE: BMY) is a global biopharmaceutical company in the pharmaceutical preparation manufacturing industry. According to company disclosures, its mission is to discover, develop and deliver medicines that help patients prevail over serious diseases. The company’s common stock and multiple series of senior notes are listed on the New York Stock Exchange, reflecting an established presence in public capital markets.
Bristol Myers Squibb focuses on therapies for serious conditions across several therapeutic areas. Company communications describe a strong emphasis on cardiovascular disease, oncology and immune-related disorders. In particular, the firm highlights immuno-oncology as a key area of drug development, with immuno-oncology medicines positioned as important treatment options in multiple cancer types. The company also notes that a significant portion of its sales are generated in the United States.
Core business and therapeutic focus
The company states that it discovers, develops and markets drugs for cardiovascular conditions, cancer and immune disorders. Within cardiovascular disease, Bristol Myers Squibb co-promotes Eliquis (apixaban), an oral anticoagulant used to reduce the risk of stroke and blood clots in adults with certain types of atrial fibrillation, to help prevent and treat deep vein thrombosis and pulmonary embolism in adults, and to treat and reduce the risk of recurrent venous thromboembolism in children from birth and older after initial anticoagulant treatment. Eliquis is described as a widely prescribed oral blood thinner in the United States.
In oncology and hematology, Bristol Myers Squibb has built a portfolio that includes immuno-oncology agents and cell therapies. Opdivo (nivolumab), a programmed death-1 (PD-1) immune checkpoint inhibitor, is described as an important treatment option across multiple cancers, with regulatory approvals in numerous tumor types such as melanoma, non-small cell lung cancer, classical Hodgkin lymphoma, renal cell carcinoma, urothelial carcinoma, colorectal cancer, hepatocellular carcinoma, esophageal and gastroesophageal cancers and others, based on specific indications outlined in prescribing information. The company also markets the Opdivo plus Yervoy (ipilimumab) combination regimen in several settings.
In cell therapy, Bristol Myers Squibb develops and commercializes Breyanzi (lisocabtagene maraleucel; liso-cel), a CD19-directed chimeric antigen receptor (CAR) T cell therapy. Breyanzi is indicated in the United States for adult patients with certain relapsed or refractory large B-cell lymphomas after specified prior therapies, as well as for relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma, follicular lymphoma, mantle cell lymphoma and marginal zone lymphoma after defined prior lines of systemic therapy. Company materials emphasize that Breyanzi is administered as a one-time infusion following a multi-step treatment process that includes T cell collection, genetic modification, lymphodepletion and post-infusion monitoring.
Pipeline and research areas
Bristol Myers Squibb reports active research and development programs across hematology, oncology, cardiovascular disease and neuroscience. In hematology and lymphoma, the company is advancing targeted protein degradation agents such as the investigational CELMoD agent golcadomide and the BCL6 ligand-directed degrader BMS-986458, with clinical data presented in aggressive B-cell lymphoma, follicular lymphoma and diffuse large B-cell lymphoma. These programs are being studied in combination with established regimens such as R-CHOP and rituximab, as well as in monotherapy settings in relapsed or refractory non-Hodgkin lymphoma.
In cardiology, Bristol Myers Squibb develops Camzyos (mavacamten), described as a selective, reversible, allosteric inhibitor of cardiac myosin that targets the pathophysiology of hypertrophic cardiomyopathy by reducing left ventricular outflow tract obstruction and improving cardiac filling pressures in obstructive hypertrophic cardiomyopathy (oHCM). Camzyos is indicated in the United States for adults with symptomatic New York Heart Association class II–III oHCM and has been studied extensively in clinical trials. The company recently announced positive topline results from the Phase 3 SCOUT-HCM trial, the first randomized, placebo-controlled study of a cardiac myosin inhibitor in adolescents with symptomatic obstructive hypertrophic cardiomyopathy.
In neuroscience, Bristol Myers Squibb is advancing Cobenfy, which is described as a treatment for schizophrenia in adults and is being evaluated in the ADEPT clinical program for psychosis associated with Alzheimer’s disease. The ADEPT-2 Phase 3 trial is a multicenter, randomized, double-blind, placebo-controlled study assessing safety and efficacy in psychosis associated with Alzheimer’s disease dementia, with endpoints focused on neuropsychiatric symptom scales and clinical global impression measures.
Collaborations and external innovation
The company supplements its internal research with collaborations. For example, Bristol Myers Squibb has a multi-target collaboration with Terray Therapeutics that uses Terray’s EMMI platform, which combines high-throughput chemical experimentation with AI-driven analysis to accelerate small molecule discovery. This collaboration is described as aiming to identify and optimize novel molecules for difficult-to-drug targets in areas of significant unmet medical need.
Regulatory and market footprint
Bristol Myers Squibb’s products are approved in multiple countries and regions, as reflected in company statements. Camzyos is noted as being approved by regulatory bodies in more than 50 countries and regions across five continents for adult symptomatic obstructive hypertrophic cardiomyopathy, and Opdivo is described as approved in more than 65 countries, including the United States, the European Union, Japan and China. Breyanzi has approvals in the United States and several other jurisdictions, including Japan, the European Union, Switzerland, Israel, the United Kingdom and Canada for specified lymphoma indications.
The company’s securities filings confirm that Bristol-Myers Squibb Company is the parent guarantor of multiple series of euro-denominated senior notes issued by a wholly owned Irish subsidiary, BMS Ireland Capital Funding Designated Activity Company. These notes, along with various U.S.-listed notes and Celgene contingent value rights, are registered on the New York Stock Exchange, underscoring the firm’s use of global debt markets to support its operations and capital allocation activities.
Capital allocation and shareholder returns
Bristol Myers Squibb’s board of directors declares regular dividends on its common and preferred stock. In a recent announcement, the company reported a quarterly dividend on its common stock and noted that it has paid dividends for many consecutive years, with a long history of annual increases. The company also conducts tender offers and other transactions involving its outstanding notes, and issues new debt securities under an indenture structure to manage its capital structure and fund corporate purposes, including repurchases, repayments or redemptions of existing notes.
Risk management and safety programs
Given the nature of its therapies, Bristol Myers Squibb describes extensive safety and risk management programs. For Camzyos, the company highlights a boxed warning for risk of heart failure due to systolic dysfunction and notes that the medicine is available only through the CAMZYOS Risk Evaluation and Mitigation Strategy (REMS) Program, which requires certification of prescribers and pharmacies, patient enrollment and ongoing monitoring. For Eliquis, Opdivo and Breyanzi, the company provides detailed important safety information, including boxed warnings for bleeding risk with Eliquis and for cytokine release syndrome, neurologic toxicities and secondary hematological malignancies with Breyanzi. These disclosures outline monitoring requirements, contraindications, drug interactions and management approaches for adverse events.
Geographic base and corporate identity
Regulatory filings list Bristol-Myers Squibb Company’s principal offices in Princeton, New Jersey. The company identifies itself as a global biopharmaceutical enterprise and emphasizes a mission of transforming patients’ lives through science. Public communications reiterate a focus on bold science, serious diseases and collaboration with healthcare providers and policymakers, including agreements with the U.S. government to improve affordability and access to certain medicines such as Eliquis for Medicaid beneficiaries.
FAQs about Bristol Myers Squibb (BMY)
- What does Bristol Myers Squibb do?
Bristol Myers Squibb discovers, develops and markets prescription medicines for serious diseases, with stated focus areas that include cardiovascular disease, cancer and immune-related disorders. Its portfolio includes small molecules, biologics and cell therapies. - Which therapeutic areas are most important for Bristol Myers Squibb?
Company materials highlight cardiovascular health, hematology and oncology, immuno-oncology and neuroscience as key areas. Examples include Eliquis in cardiovascular disease, Opdivo and the Opdivo plus Yervoy regimen in multiple cancers, Camzyos in obstructive hypertrophic cardiomyopathy, Breyanzi in B-cell lymphomas and Cobenfy in neuropsychiatric conditions. - On which exchange does BMY trade?
According to its SEC filings, Bristol-Myers Squibb Company’s common stock, with a par value of $0.10 per share, is listed on the New York Stock Exchange under the trading symbol BMY. - How does Bristol Myers Squibb use collaborations in its business?
The company engages in collaborations with other organizations to advance drug discovery and development. For example, it collaborates with Terray Therapeutics to apply an AI-enabled experimental platform to small molecule discovery targeting difficult-to-drug proteins. - What is Camzyos and what condition does it address?
Camzyos (mavacamten) is described as a selective, reversible, allosteric inhibitor of cardiac myosin that targets the pathophysiology of hypertrophic cardiomyopathy by reducing left ventricular outflow tract obstruction and improving cardiac filling pressures. It is indicated in the United States for adults with symptomatic New York Heart Association class II–III obstructive hypertrophic cardiomyopathy to improve functional capacity and symptoms, and has been studied in adolescents with symptomatic obstructive hypertrophic cardiomyopathy in the SCOUT-HCM trial. - What is Breyanzi and how is it used?
Breyanzi (lisocabtagene maraleucel; liso-cel) is a CD19-directed CAR T cell therapy made from a patient’s own T cells, which are collected, genetically modified and reinfused as a one-time treatment. It is indicated in the United States for adult patients with certain relapsed or refractory large B-cell lymphomas and for relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma, follicular lymphoma, mantle cell lymphoma and marginal zone lymphoma after specified prior therapies. - What role does Opdivo play in Bristol Myers Squibb’s portfolio?
Opdivo (nivolumab) is a PD-1 immune checkpoint inhibitor that uses the body’s immune system to help restore anti-tumor immune responses. It has a broad development program and is approved in multiple cancers, including melanoma, non-small cell lung cancer, classical Hodgkin lymphoma and several gastrointestinal and genitourinary cancers, often alone or in combination with Yervoy or chemotherapy. - How does Bristol Myers Squibb approach safety and risk management for its medicines?
The company provides detailed prescribing information and important safety information for its products, including boxed warnings where required. For certain therapies such as Camzyos and Breyanzi, Bristol Myers Squibb supports structured risk management programs, including a REMS program for Camzyos and specific monitoring recommendations for cytokine release syndrome and neurologic toxicities with Breyanzi. - What is Bristol Myers Squibb’s relationship with the U.S. government regarding Eliquis?
The company announced an agreement with the U.S. government under which Eliquis will be made available for free to the Medicaid program for a defined period, accompanied by a donation of Eliquis active pharmaceutical ingredient to support supply resilience and other commitments related to pricing approaches and patient access. - How does Bristol Myers Squibb return capital to shareholders?
Bristol Myers Squibb’s board of directors declares regular quarterly dividends on its common and preferred stock, and the company has disclosed a long history of consecutive dividend payments and annual increases. It also undertakes debt tender offers and issues new notes as part of its broader capital management strategy.